Contineum
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Contineum and other ETFs, options, and stocks.About CTNM
Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S.
CEOCarmine N. Stengone
CEOCarmine N. Stengone
Employees41
Employees41
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded2017
Founded2017
Employees41
Employees41
CTNM Key Statistics
Market cap511.07M
Market cap511.07M
Price-Earnings ratio-4.83
Price-Earnings ratio-4.83
Dividend yield—
Dividend yield—
Average volume241.62K
Average volume241.62K
High today$11.90
High today$11.90
Low today$10.69
Low today$10.69
Open price$10.97
Open price$10.97
Volume406.19K
Volume406.19K
52 Week high$13.57
52 Week high$13.57
52 Week low$3.35
52 Week low$3.35
Stock Snapshot
As of today, Contineum(CTNM) shares are valued at $11.76. The company's market cap stands at 511.07M, with a P/E ratio of -4.83.
On 2026-01-14, Contineum(CTNM) stock traded between a low of $10.69 and a high of $11.90. Shares are currently priced at $11.76, which is +10.0% above the low and -1.2% below the high.
Contineum(CTNM) shares are trading with a volume of 406.19K, against a daily average of 241.62K.
During the past year, Contineum(CTNM) stock moved between $3.35 at its lowest and $13.57 at its peak.
During the past year, Contineum(CTNM) stock moved between $3.35 at its lowest and $13.57 at its peak.
Analyst ratings
86%
of 7 ratingsBuy
85.7%
Hold
14.3%
Sell
0%
People also own
Based on the portfolios of people who own CTNM. This list is generated using Robinhood data, and it’s not a recommendation.